Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|February 2, 2020
- Pharmaceutical Technology-02-02-2020
- Volume 44
- Issue 2
Blister Packaging Machine
The Eagle-Omni blister machine from Maruho Hatsujyo Innovations can be used for packaging development, materials testing and production, and forming, sealing, and punching operations at sequential stations.
The Eagle-Omni blister machine from Maruho Hatsujyo Innovations can be used for packaging development, materials testing and production, and forming, sealing, and punching operations at sequential stations.
The device, which can produce up to 20 blisters per minute, is 1.6 meters tall, has a format area of 150x95 mm, and a forming depth of 30mm or 40mm. It can handle forming materials such as PVC, PVDC, ACLAR, PP, PET, and ALU, and all typical lidding substrates including ALU, paper, PVC, PET, and laminates.
The machine is also capable of manual prototyping and fully automated operation and allows for low-cost prototyping, recipe-driven format change, easy changeover, and various feeding solutions.
Articles in this issue
over 6 years ago
Pre-Clinical: Laying the Right Foundationover 6 years ago
Global Supply Issues Create Challengesover 6 years ago
The Call for a Rapid Responseover 6 years ago
ICH to Revise Quality Risk Management Guidelineover 6 years ago
Brexit: What Happens Next for Pharma?over 6 years ago
Of Serious Concern?over 6 years ago
Best Practices in Using Isolator Technologyover 6 years ago
Data Management Practicesover 6 years ago
Pivoting Triple Shaft MixerRelated to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5